SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

AstraZeneca PLC AZNCF OTC

Other OTC • Healthcare • Drug Manufacturers - General • GB • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

AstraZeneca PLC (AZNCF) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $189.90. It has a SharesGrow Score of 69/100, indicating a above average investment profile with 5 out of 7 criteria passed.

Financials: revenue is $58.7B, +10%/yr average growth. Net income is $10.2B, growing at +48.2%/yr. Net profit margin is 17.4% (healthy). Gross margin is 81.9% (+9.8 pp trend).

Balance sheet: total debt is $29.6B against $48.7B equity (Debt-to-Equity (D/E) ratio 0.61, moderate). Current ratio is 0.94 (tight liquidity). Debt-to-assets is 26%. Total assets: $114.1B.

Analyst outlook: 17 / 36 analysts rate AZNCF as buy (47%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 60/100 (Pass), Growth 90/100 (Pass), Past 100/100 (Pass), Health 50/100 (Partial), Moat 94/100 (Pass), Future 20/100 (Fail), Income 70/100 (Pass).

AZNCF SharesGrow Score Overview

69/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 60/100

Valuation — P/E, PEG, Forward PEG

GROWTH 90/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 50/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 94/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 70/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — AZNCF

AZNCF trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

AZNCF: +10%/yr revenue is, +48.2%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

AZNCF: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet AZNCF: Debt-to-Equity (D/E) ratio 0.61 (moderate), Current ratio is 0.94 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

AZNCF: Gross margin is 81.9% (+9.8 pp trend), $294B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 94/100. ≥ 70 = Pass.

View details →

Analyst outlook: 17 / 36 analysts rate AZNCF as buy (47%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

AZNCF: Net profit margin is 17.4%. healthy (≥15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range122.26-209.48

Volume1.43M

Avg Volume (30D)161.84K

Market Cap$294.4B

Beta (1Y)0.19

Dividend Yield$3.1400

Share Statistics

EPS (TTM)6.60

Shares Outstanding$1.55B

IPO Date2009-02-13

Employees94,300

CEOPascal Claude Roland Soriot

Financial Highlights & Ratios

Revenue (TTM)$58.74B

Gross Profit$48.11B

EBITDA$19.83B

Net Income$10.23B

Operating Income$13.74B

Total Cash$5.74B

Total Debt$29.62B

Net Debt$23.91B

Total Assets$114.07B

Price / Earnings (P/E)28.8

Price / Sales (P/S)5.01

Analyst Forecast

Rating ConsensusBuy

Analysts Covering36

Buy 47% Hold 42% Sell 11%

Company Info

CountryGB

ExchangeOther OTC

CurrencyUSD

ISINGB0009895292

Price Chart

AZNCF

AstraZeneca PLC ↗ · Other OTC

Healthcare • Drug Manufacturers - General

122.26 52WK RANGE 209.48

People Also View

Roche Holding AG

Roche Holding AG

Roche Holding AG

Daiichi Sankyo Company, Limited

Astellas Pharma Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message